Holen Sie sich die Stockscreener-App
8.33
4.14%
-0.36
Handel nachbörslich:
8.33
Schlusskurs vom Vortag:
$8.69
Offen:
$8.56
24-Stunden-Volumen:
91,729
Relative Volume:
0.69
Marktkapitalisierung:
$410.24M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-12.39
EPS:
-0.6724
Netto-Cashflow:
1W Leistung:
-9.65%
1M Leistung:
-31.50%
6M Leistung:
-21.86%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.15
$8.86
1-Wochen-Bereich:
$8.15
$9.65
52-Wochen-Spanne:
$7.97
$17.82
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Firmenname
Agomab Therapeutics Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare AGMB vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGMB
Agomab Therapeutics Nv Adr
|
8.33 | 410.24M | 0 | 0 | 0 | -0.6724 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-25 | Eingeleitet | Piper Sandler | Overweight |
| 2026-08-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-07-23 | Eingeleitet | B. Riley Securities | Buy |
| 2026-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-03 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Agomab Therapeutics Nv Adr Aktie (AGMB) Neueste Nachrichten
What Does AgomAb (AGMB)'s +5.17% Surge Signal for the Sector? 2026-09-17Key Reversal Day - dars.gov.et
AgomAb Therapeutics Director Marino Garcia Granted 57,482 Stock Options - Kalkine Media
Director at Agomab Therapeutics NV (AGMB) receives 57K stock options - Stock Titan
Agomab Therapeutics (AGMB) awards long-dated stock options to director - Stock Titan
Agomab Shareholders Approve New Board Members and Pre-IPO Warrant Adjustment - TipRanks
ETFs Investing in AgomAb Therapeutics NV ADR Stocks - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS) - The Globe and Mail
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionMcClellan Summation - siam.in
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionMomentum Breakout Ideas - dars.gov.et
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionFast Moving Stocks - dars.gov.et
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - theglobeandmail.com
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Agomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - theglobeandmail.com
B.Riley initiates Agomab Therapeutics stock with buy rating - Investing.com India
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), COMPASS Pathways (CMPS) and Alkermes (ALKS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Volatility & Greeks - Finviz
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Latest SEC Filings - Finviz
AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView
AGMB Forecast — Price Target — Prediction for 2027 - TradingView
Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com
Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
AGMB - Finviz
Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.
Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate
Double BottomStock ScreenerCharts - Finviz
Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - GlobeNewswire Inc.
Finanzdaten der Agomab Therapeutics Nv Adr-Aktie (AGMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agomab Therapeutics Nv Adr-Aktie (AGMB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kemula Pierre Thadee Victor | Chief Financial Officer |
Oct 06 '26 |
Buy |
8.59 |
10,000 |
85,940 |
10,000 |
| Knotnerus Tim Jasper | Chief Executive Officer |
Oct 06 '26 |
Buy |
8.70 |
5,000 |
43,500 |
21,823 |
| Epstein David R | Director |
Oct 06 '26 |
Buy |
8.70 |
5,000 |
43,500 |
10,000 |
| Epstein David R | Director |
Oct 05 '26 |
Buy |
8.57 |
5,000 |
42,850 |
5,000 |
| Knotnerus Tim Jasper | Chief Executive Officer |
Oct 05 '26 |
Buy |
8.48 |
6,000 |
50,880 |
16,823 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):